TGF-β inhibitors for the treatment of cancer

被引：64
|
作者：
Lahn, M [1 ]
Kloeker, S [1 ]
Berry, BS [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Therapeut Area Oncol, Indianapolis, IN 46285 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 06期
关键词：
antisense oligonucleotide; cancer; clinical Studies; knockout mice; monoclonal antibodies; TGF-beta; TGF-beta RI kinase inhibitors;
D O I：
10.1517/13543784.14.6.629
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small molecules. in this review, the current stage of development of each known TGF-beta inhibitor will be discussed. As part of the risk/benefit assessment of TGF-beta inhibitors, the known effects of TGF-beta deficiency in mice, non-clinical toxicology studies with TGF-beta inhibitors in rats, and the clinical studies with monoclonal antibodies against TGF-beta will be summarised.
引用
收藏
页码：629 / 641
页数：13
相关论文
共 50 条
  • [41] Mechanisms of TGF-β receptor inactivation and development of resistance to TGF-β in human gastric cancer
    Kim, SJ
    Yang, HK
    Im, YH
    Bang, YJ
    Yang, HK
    3RD INTERNATIONAL GASTRIC CANCER CONGRESS, 1999, : 81 - 90
  • [42] Transfection of the type I TGF-β receptor restores TGF-β responsiveness in pancreatic cancer
    Wagner, M
    Kleeff, J
    Lopez, ME
    Bockman, I
    Massaqué, J
    Korc, M
    INTERNATIONAL JOURNAL OF CANCER, 1998, 78 (02) : 255 - 260
  • [43] Transforming growth factor β isoforms (TGF-β1, TGF-β2, TGF-β3) messenger RNA expression in laryngeal cancer
    Kapral, Malgorzata
    Strzalka, Barbara
    Kowalczyk, Magorzata
    Jurzak, Magdalena
    Mazurek, Urszula
    Gierek, Tatiana
    Paluch, Jaroslaw
    Markowski, Jaroslaw
    Swiatkowska, Longina
    Weglarz, Ludmila
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2008, 29 (04) : 233 - 237
  • [44] Reversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
    Slawomir Wojtowicz-Praga
    Investigational New Drugs, 2003, 21 : 21 - 32
  • [45] Targeting the TGF-β Receptor with Kinase Inhibitors for Scleroderma Therapy
    Cong, Lin
    Xia, Zhi-Kuan
    Yang, Rong-Ya
    ARCHIV DER PHARMAZIE, 2014, 347 (09) : 609 - 615
  • [46] Targeting TGF-β signaling for the treatment of fibrosis
    Gyoerfi, Andrea Hermina
    Matei, Alexandru-Emil
    Distler, Joerg H. W.
    MATRIX BIOLOGY, 2018, 68-69 : 8 - 27
  • [47] Reversal of tumor-induced immunosuppression by TGF-β inhibitors
    Wojtowicz-Praga, S
    INVESTIGATIONAL NEW DRUGS, 2003, 21 (01) : 21 - 32
  • [48] 2-Aminoimidazoles inhibitors of TGF-β receptor 1
    Bonafoux, Dominique
    Chuaqui, Claudio
    Boriack-Sjodin, P. Ann
    Fitch, Chris
    Hankins, Gretchen
    Josiah, Serene
    Black, Cheryl
    Hetu, Gregg
    Ling, Leona
    Lee, Wen-Cherng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 912 - 916
  • [49] Targeting TGF-β for treatment of osteogenesis imperfecta
    Song, I-Wen
    Nagamani, Sandesh Cs
    Nguyen, Dianne
    Grafe, Ingo
    Sutton, Vernon Reid
    Gannon, Francis H.
    Munivez, Elda
    Jiang, Ming-Ming
    Tran, Alyssa
    Wallace, Maegen
    Esposito, Paul
    Musaad, Salma
    Strudthoff, Elizabeth
    McGuire, Sharon
    Thornton, Michele
    Shenava, Vinitha
    Rosenfeld, Scott
    Huang, Shixia
    Shypailo, Roman
    Orwoll, Eric
    Lee, Brendan
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (07):
  • [50] TGF-β Signaling in Progression of Oral Cancer
    Guo, Yuanyuan
    Xu, Tiansong
    Chai, Yujuan
    Chen, Feng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (12)
12345